Needham raises target for NeoGenomics stock from USD 19.00 to USD 22.00
Published on 10/20/2026 at 20:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Needham raised its NeoGenomics target from USD 19.00 to USD 22.00 on October 6, 2026.
- The target stands 31.50 percent above the Nasdaq price of USD 16.73 on October 20, 2026.
- NeoGenomics stock traded at EUR 14.87 at Lang & Schwarz on October 20, 2026 at 8:41 p.m. CEST.
- NeoGenomics is scheduled to report third-quarter 2026 results on October 28, 2026.
Needham raised its price target for NeoGenomics stock from USD 19.00 to USD 22.00 on October 6, 2026, while maintaining a Buy rating, according to Investing.com. The target stands 31.50 percent above NeoGenomics' Nasdaq price of USD 16.73 at 2:45 p.m. EDT on October 20, 2026. At Lang & Schwarz, the stock traded at EUR 14.87 on October 20, 2026 at 8:41 p.m. CEST.
Analyst target leaves room
Needham's revised target is the clearest valuation reference for the stock after a strong operating update. The USD 3.00 increase represents a 15.79 percent rise from the firm's previous target of USD 19.00, and the new target is 31.50 percent above the Nasdaq price cited above.
MarketBeat reported that six analysts rated NeoGenomics Buy, three rated it Hold and one rated it Sell on October 6, 2026. The outlet listed an average target of USD 18.17, which is below Needham's USD 22.00 objective but above the Nasdaq price of USD 16.73.
Revenue reached USD 201.66 million
NeoGenomics reported second-quarter 2026 revenue of USD 201.66 million, up 11.20 percent from the same quarter a year earlier, while adjusted earnings per share reached USD 0.05 versus USD 0.03 consensus, according to MarketBeat. The quarter ended June 30, 2026, and the revenue figure exceeded the cited consensus estimate of USD 196.93 million.
October 28 results date
NeoGenomics is scheduled to report third-quarter 2026 results on October 28, 2026, with its conference call set for 4:30 p.m. EDT. The company said in an October 5, 2026 filing that preliminary third-quarter revenue was expected to reach USD 209.00 million and next-generation sequencing revenue growth about 28.00 percent; the same release linked the update to the planned January 4, 2027 leadership transition, according to NeoGenomics.
Comparison with peers
NeoGenomics: up 1.89 percent, P/E minus 8.43, market capitalization USD 2.2 billion on October 20, 2026.
Quest Diagnostics (NYSE, USD): up 0.37 percent, P/E 25.02, market capitalization USD 26.0 billion on October 20, 2026.
Labcorp Holdings (NYSE, USD): up 0.77 percent, P/E 26.56, market capitalization USD 26.1 billion on October 20, 2026.
Stock trades in two currencies
The Nasdaq quotation was USD 16.73 at 2:45 p.m. EDT on October 20, 2026, while the German after-hours indication was EUR 14.87 at 8:41 p.m. CEST. NeoGenomics operates in oncology diagnostics and provides testing services to hospitals, physicians, pathologists and pharmaceutical companies.
The further course of trading is shown by the continuously updated real-time quote of NeoGenomics stock.
NeoGenomics stock facts
- Company: NeoGenomics, Inc.
- ISIN: US64049M2098
- Ticker: NEO
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 20, 2026, 8:41 p.m. CEST): EUR 14.87
- Market capitalization: USD 2.2 billion (as of October 20, 2026)
- 52-week range: USD 7.07-20.15 (as of October 20, 2026)
- Sector / Industry: Healthcare / Medical Diagnostics and Research
- Next earnings date: October 28, 2026
Market context: Market report S&P 500.
